Home >
AEPSO Argentina launches digital map to find people with psoriasis in the country
2015/04/09 - News from patients associations
Psoriasis, recognised today by the World Health Organization (WHO) as a painful and incapacitating non communicable chronic disease, affects more than 800 000 Argentineans. AEPSO (Asociación Civil para el Enfermo de Psoriasis) celebrates its 10th anniversary raising awareness and supporting the rights of the patients. In order to better know what is going on with the disease in Argentina and to reach out the different communities, AEPSO has launched an interactive digital map, accessible through Facebook, that aims to identify and connect all psoriasis patients in each corner of the country.
Silvia Fernández Barrio, president and founder of AEPSO, has acknowledged that social networks have contributed to show unknown realities that they wish to work on for the benefit of the patients: “This is why this map came about, a tool that will give precise information where persons with psoriasis in Argentina live, and thus better help each one of them, guide them to informed professionals and to centres where they can get the treatment they need, as well as to create ties among patients going through the same experience in their community. In a territory as vast and with different realities we have to take advantage of technology as an opportunity to shorten distance and time”.
During the next 10 years, Beatriz Larrea, Executive Director of AEPSO, said that “we would like to achieve a presence of groups of people with psoriasis in every region of the country. That there are patients gathering, giving their time and sharing their experiences and knowledge in order to help others to better cope with their reality”.
One of the greatest obstacles that a psoriasis patients still faces is ignorance. There are patients that do not see a doctor because of the old prejudice that this is a disease that there is nothing you can do, so they give up. “Nothing could be farther from the truth”, exclaimed Silvia Fernández Barrio, adding “those people we must reach them through AEPSO; so that they know who we are, that we are here to help them, guide them, provide them with information and suggest where they can start to treat themselves. Their life can change, and is going to change”.
“We strive to achieve that no patient across the country lives withouth diagnosis or treatment; we have a lot of work ahead of us, but we know this is the way”, added the president of AEPSO.
You can find the map at:
https://www.facebook.com/pages/AEPSO/103448854973?sk=app_1497274527196166
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Our ambition in a changing landscape of psoriasis treatments.
van de Kerkhof PCM et al.
Our ambition in a changing landscape of psoriasis treatments.
J Dermatolog Treat.
2020 Mar , 31, (2):105-107.
CARD14/CARMA2sh and TANK differentially regulate poly(I:C)-induced inflammatory reaction in keratinocytes.
J. Cell. Physiol..
2020 Mar , 235, (3):1895-1902.
CARD14/CARMA2sh (CARMA2sh) is a scaffold protein whose mutations are associated with the onset of human genetic psoriasis and other inflammatory skin disorders. Here we show that the immunomodulatory adapter protein TRAF family member-associated NF-κB activator (TANK) forms a complex with CARMA2sh and MALT1 in a human keratinocytic cell line. We also show that CARMA2 and TANK are individually required to activate the nuclear factor κB (NF-κB) response following exposure to (...)
see on pubmed
Prohibitin 1 interacts with signal transducer and activator of transcription 3 in T-helper 17 cells.
Immunol. Lett..
2020 Mar , 219:8-14.
T-helper 17 (Th17) cells are involved in the occurrence and development of several inflammation-associated diseases. Interleukin (IL)-17, the main cytokine secreted by differentiated Th17 cells, mediates immunoreactions and plays important roles in immunological diseases, including psoriasis, rheumatic arthritis, and inflammatory bowel disease. The maturation and stabilization of the differentiated Th17 cell phenotype are associated with the expression of IL-17A, which is induced by the (...)
see on pubmed
on Atopic Dermatitis
Off-label studies on apremilast in dermatology: a review.
Maloney NJ et al.
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat.
2020 Mar , 31, (2):131-140.
Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify (...)
see on pubmed
Atopic dermatitis induces anxiety- and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice.
Prog. Neuropsychopharmacol. Biol. Psychiatry.
2020 Mar 02, 98:109818.
Clinically, it has been reported that atopic dermatitis (AD) has been linked with negative emotional problems such as depression and anxiety, thereby reducing the quality of life, but little is known about the molecular mechanism that underlies AD-associated emotional impairments. We sought to determine whether AD could induce anxiety- and depressive-like symptoms in mice and to identify pertinent signaling changes in brain reward circuitry. AD-like lesions were induced by the repeated (...)
see on pubmed
Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis: A randomized clinical trial.
J Ethnopharmacol.
2020 Mar 25, 250:112477.
Indigo naturalis, a herbal medicine with a history of use dating back to ancient times, may be a good alternative topical treatment for atopic dermatitis (AD).
see on pubmed
